The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street
This article was originally published in RPM Report
Executive Summary
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
You may also be interested in...
The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure
The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.
Capping Off The Rebate Debate: Will 2019 Price Push End With Co-Pay Cap?
The pharmaceutical industry and its strongest critics have long agreed on one thing: Medicare Part D would be improved if there was a cap on spending by beneficiaries. Now, there is an unlikely path that may make it surprisingly easy to get it done.
Trump’s Election Could Bring ‘Best Of Times’ For Pharma
Obama administration wasn’t bad but had ‘less than thrilling moments,’ BIO exec says; former FDA Commissioner says leadership, not scientific, skill is key attribute for next agency chief.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: